Drug Profile

Ustekinumab biosimilar - Outlook Therapeutics

Alternative Names: ONS-3040

Latest Information Update: 29 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oncobiologics
Developer Outlook Therapeutics
Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Psoriasis

Most Recent Events

29 Aug 2023 Discontinued - Preclinical for Psoriasis in USA (SC)
28 Feb 2020 No recent reports of development identified for preclinical development in Psoriasis in USA (SC, Injection)
03 Dec 2018 Oncobiologics is now called Outlook Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com